Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hösbach

6 clinical trials in Hösbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hösbach at a glance
6
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

6 trials in Hösbach

Open in trial search

Plasma cell myeloma refractory

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Breast cancer+1

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Institut fuer Frauengesundheit GmbH

Gastrooesophageal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hormone receptor positive HER2 negative breast cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Universitaetsklinikum Ulm AöR

Rectal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Hösbach

What the registry says about research in the country

01 Hösbach
Neoplasms and Oncology
Clinical research in Hösbach is focused on cancer care, with studies centered on improving treatment outcomes, survival, and long-term disease control across several solid tumors and blood cancers. Breast cancer, including hormone receptor–positive and HER2-negative early, locally advanced, and metastatic disease Non-Small Cell Lung Cancer with attention to previously treated PD-L1-positive disease Colorectal cancer, especially locally advanced rectal cancer Multiple myeloma in the relapsed or refractory setting These trials are mainly evaluating new treatment strategies, comparing therapy effectiveness, and supporting better disease management for patients in a recruiting research setting.
Breast Cancer Research
A major share of the trial activity examines breast cancer, especially HR-positive and HER2-negative disease, with the goal of delaying progression and improving survival in both advanced and earlier-stage settings. Early breast cancer at risk of recurrence Locally advanced or metastatic breast cancer Endocrine therapy and treatment persistence Improving outcomes through better side effect management and patient support The studies include combinations of established cancer therapies and educational approaches designed to help patients stay on treatment longer and manage care more effectively.
Lung Cancer Studies
Research in non-small cell lung cancer is examining new options for patients who have already received treatment, with a focus on extending survival and comparing treatment benefit against standard care. NSCLC with prior treatment exposure PD-L1-positive tumor populations Comparative evaluation of anti-cancer therapies Assessment of overall survival and treatment effectiveness These trials aim to clarify whether newer approaches can offer better disease control for patients with advanced lung cancer.
Colorectal Cancer and Surgical Treatment
Studies in locally advanced rectal cancer are exploring how treatment planning before and after surgery can improve cancer control and reduce the chance of recurrence. Rectal cancer with low risk for local failure Optimizing the sequence of surgery and chemotherapy Measuring disease-free survival Reducing recurrence and supporting long-term outcomes This line of research is intended to refine standard care and identify the most effective way to combine treatments for better recovery.
Multiple Myeloma Investigation
Another key area is relapsed or refractory multiple myeloma, where trials are testing combination therapies to improve response in patients whose disease has returned or is no longer responding well. RRMM treatment strategies Combination therapy in adult patients Evaluating response rate Supporting better control of advanced blood cancer The research is aimed at expanding treatment options and finding more effective ways to manage difficult-to-treat disease.
Patient Support and Treatment Persistence
Beyond drug-focused studies, trials in this city also examine how education and coaching can help patients remain on therapy longer, reflecting a growing interest in practical support for cancer care. Ribociclib treatment persistence Patient education and personalized coaching Reducing premature treatment discontinuation Improving day-to-day adherence and care experience This research highlights the importance of combining medical treatment with structured support to improve real-world outcomes.
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.